MAGELLAN - Multicenter, rAndomized, Parallel Group Efficacy and Safety for the Prevention of VTE in Hospitalized Medically iLL Patients Comparing rivaroxabAN With Enoxaparin.

Trial Profile

MAGELLAN - Multicenter, rAndomized, Parallel Group Efficacy and Safety for the Prevention of VTE in Hospitalized Medically iLL Patients Comparing rivaroxabAN With Enoxaparin.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms MAGELLAN
  • Sponsors Bayer HealthCare
  • Most Recent Events

    • 07 Feb 2013 Results published in the New England Journal of Medicine.
    • 03 Jul 2012 Company added in the association field as reported by EudraCT.
    • 28 Jul 2011 Results of an analysis of treatment in different patient subgroups presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top